I think GSK had a stab at a herpes vaccine a few years ago. They hit a brick wall at the Phase 3 trial phase. A GSK like Big Pharma will be needed to fund late stage trials.
Will be interesting to see if authorities include a future preventative herpes vaccine on the immunization schedule. It will need to satisfy a number of requirements including whether the vaccination is a priority. Apart from neonate herpes, herpes doesnt damage any vital organs and doesnt lead to death in people so, in a world of tight health budgets and competing health priorities, it may not be considered a huge priority.
I personally believe because it has relatively minor morbidity issues I reckon the health authorities might be inclined to wait until they have years (maybe decades) of data behind it before its put on a universal vaccination schedule. It doesnt prevent people from getting a vax in the meantime, they just have to pay for it from their own pocket.
- Forums
- ASX - By Stock
- AVR
- 2:1000000 million chance of getting brain damage from Herpes
2:1000000 million chance of getting brain damage from Herpes, page-67
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.65 |
Change
-0.350(2.33%) |
Mkt cap ! $309.6M |
Open | High | Low | Value | Volume |
$14.50 | $14.94 | $14.25 | $1.266M | 86.85K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 126 | $14.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.65 | 99 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 126 | 14.250 |
2 | 385 | 14.000 |
1 | 250 | 13.750 |
1 | 219 | 13.670 |
1 | 160 | 13.600 |
Price($) | Vol. | No. |
---|---|---|
14.650 | 99 | 1 |
14.800 | 1000 | 1 |
15.000 | 500 | 1 |
15.150 | 149 | 1 |
15.500 | 44 | 1 |
Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |